Can you discuss and explain recent clinical evidence focused on anti-TNF inhibitor biosimilars for infliximab in the setting of RA; and by extrapolation, AS, IBD, and related conditions?

Can you discuss and explain recent clinical evidence focused on anti-TNF inhibitor biosimilars for infliximab in the setting of RA; and by extrapolation, AS, IBD, and related conditions?

Can you discuss and explain the study design, rationale, results, and practical clinical implications of the most recent clinical evidence focused on anti-TNF inhibitor biosimilars for infliximab in the setting of RA; and by extrapolation, AS, IBD, and related conditions? And what degree of price reductions have we observed with anti-TNF biosimilars?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stanley Cohen, MD

Stanley Cohen, MD

Clinical Professor
Department of Internal Medicine
UT Southwestern Medical Center
Co-Director of the Division of Rheumatology
Presbyterian Hospital
Dallas, Texas